Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. - Wikidata - wikimedia - TriplyDB

Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy.

Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy.

http://www.wikidata.org/entity/Q33257976

about

Intermedin is a new angiogenic growth factor Endogenous S-nitrosothiols protect against myocardial injury Cell Therapy in Patients with Critical Limb Ischemia Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair Nitric oxide synthases: regulation and function Diabetes-associated macrovascular complications: cell-based therapy a new tool?Cardiogenic small molecules that enhance myocardial repair by stem cells.cGMP-dependent protein kinase I is crucial for angiogenesis and postnatal vasculogenesis Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial.Cell-based therapy for heart disease: a clinically oriented perspective Very small embryonic-like stem cells in cardiovascular repair.Adiponectin pretreatment counteracts the detrimental effect of a diabetic environment on endothelial progenitors.Identification of free nitric oxide radicals in rat bone marrow: implications for progenitor cell mobilization in hypertension eNOS overexpressing bone marrow cells are safe and effective in a porcine model of myocardial regeneration following acute myocardial infarction.New perspectives for the treatment of pulmonary hypertension ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells.Vasculogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential.Cell-based therapies for diabetic complications.Nitric oxide synthase gene transfer restores activity of circulating angiogenic cells from patients with coronary artery disease AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats.Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells.Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells.Inhaled NO contributes to lung repair in piglets with acute respiratory distress syndrome via increasing circulating endothelial progenitor cells.Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina.Metabolism Regulates Cellular Functions of Bone Marrow-Derived Cells used for Cardiac Therapy.Stem cell recruitment after injury: lessons for regenerative medicine.Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors The role of endothelial progenitor cells in ischemic cerebral and heart diseases.Promise of endothelial progenitor cell for treatment of diabetic retinopathy.Overexpression of Nitric Oxide Synthase Restores Circulating Angiogenic Cell Function in Patients With Coronary Artery Disease: Implications for Autologous Cell Therapy for Myocardial Infarction The impact of insulin resistance on endothelial function, progenitor cells and repair.Genetic enhancement of stem cell engraftment, survival, and efficacy.Suppression of Sproutys has a therapeutic effect for a mouse model of ischemia by enhancing angiogenesis.Endothelial progenitor cells: new perspectives and applications in cardiovascular therapies.Aging and disease as modifiers of efficacy of cell therapy.Immune system in renal injury and repair: burning the candle from both ends?The promise of cell-based therapies for diabetic complications: challenges and solutions

P2860

Q24313298-F9CFAF21-509A-4C78-A878-43D30EF997D9 Q24658413-30C6CBB8-0730-44E8-A4E4-C35C1C0F9A3F Q26795443-40E4AC07-B55A-400F-9DB9-BBF6D47D6BC5 Q27001159-7A8CC512-B3B2-4532-9E37-CFA436C95DED Q27341905-2F4A7414-B6C9-4B78-952D-178AE7B693A8 Q28247092-EC3720A5-0E7E-43B1-AF83-A33E70FE2022 Q30428895-087A6988-9921-4716-9103-D3E7E16CAB2D Q33329047-250F2E63-ED8B-4612-92FC-45569A544CD6 Q33418301-7C577D54-2D9D-44F1-9D40-78B70E52423A Q33455791-77D7B6AD-2217-46DC-8238-577C8D2E2530 Q33505911-485FD4B4-7C5A-4031-86DD-6437FD28A1F2 Q33713519-1B46C26B-773A-4840-AB00-F70989458090 Q34419924-CB1141F3-3485-4D0E-9667-804D4808E16A Q34527232-74688775-D0DC-4C61-9829-3759B2D75D73 Q34647889-A42C3393-13C5-4485-AAE5-371F4EF9AB34 Q34803600-4389F382-359F-4CA6-811D-B7CBC08315D4 Q34903204-6E5E9ABE-429D-4686-B26D-7F5DA410D734 Q34926403-95E613EC-FE04-485D-921E-524E65A625A5 Q35022016-9742475E-F42F-483A-9845-FF9A89AD8C75 Q35070554-6CEB8178-0857-46CB-B50B-AFC9254A2672 Q35086114-ABFF68FA-28A5-4D03-893A-322E3EC533AE Q35089883-92BF5CB9-D238-4B31-BFDE-8459860299C3 Q35216447-DAEDBCE6-A5BC-4201-A709-0AEADFCD4A88 Q35221390-15C16801-9537-4861-9F04-A62A3F471BE9 Q35287252-17CA8D8B-D259-406F-9939-4DB48097BB85 Q35842603-5475DDBC-C13B-47BD-886D-EEF325AC0CE0 Q35925633-141C3F11-9D08-4087-A6B0-460FC08A7F6E Q36008423-10286BF2-3AF2-455B-ACC1-57962184F813 Q36599286-26278C0F-DD3E-485F-8D69-374DB651CEA8 Q36720543-07BBA33B-860B-4FCC-A128-FA3E69E2C464 Q36822315-1865BC69-CCC7-48AE-A82E-3E89B1EAEF92 Q36839005-A7724BBA-39A9-44AF-A83D-461619AC1008 Q36877532-1500B004-44E7-4F4D-BAE6-C0C764EB7959 Q36892494-46801FF6-1271-4981-956E-F5CD5201F31D Q37156670-64DBCA06-6136-4E37-9CA8-10002BC194B2 Q37173668-22260FB7-7C78-406D-9073-841B448A946D Q37176444-5C8833C0-54D1-438C-B775-FC382610B063 Q37183949-083160DC-B676-45BE-8449-2315DF05DA09 Q37202978-C2BC7E7A-819F-4A9E-8529-ABE12A9261C7 Q37276042-43BF44BE-4A94-4702-A07F-846E176A02FD

P2860

Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy.

http://www.wikidata.org/entity/Q33257976

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@ast

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@en

type

label

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@ast

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@en

prefLabel

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@ast

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@en

P1433

Q33257976-FF0E297C-0E27-451C-A68D-53B7DB0723E7

P1476

Q33257976-7A78F8E0-5F49-4238-BFC6-A9FCFF216341

P2093

Q33257976-03733FDF-0BF5-4BDA-BDC5-5C28D0B51D8B

Q33257976-08941272-ABF9-4519-9625-EA8FA08DF1C8

Q33257976-0E164A9D-90E0-4AC2-B10B-28E29BF5A059

Q33257976-1EDED290-97AF-41BA-B12B-42AA698C880F

Q33257976-473F7E9A-33ED-496E-BC64-BD4274AAC3A9

Q33257976-4D89D5FB-2E1D-4C73-8E38-76B7585E9EDD

Q33257976-DD466B25-51AB-4EF9-B874-798F7F9906C3

Q33257976-FB5814BD-B9AE-4EAF-BC9F-E1BD9EA8EF79

P2860

Q33257976-01E63032-1E72-4366-A955-2A56DE9065A7

Q33257976-14373FE7-9D4D-467A-922C-E93602F0F21C

Q33257976-1E386277-A6DD-4C09-BC19-9B9D41A1D58B

Q33257976-2033DB4D-2B04-4DFA-82CF-BCF7B93DCAED

Q33257976-2C0AD33F-3E00-4497-AFBC-2C9C187F7C9A

Q33257976-395DC3B8-8D71-407F-B587-292CE1002B9C

Q33257976-50096D03-1398-4373-B70F-448CFE3E61EC

Q33257976-5898CC53-D8B8-4AB7-A07C-54C9E93FE22D

Q33257976-5AD04318-F2CE-4B3D-B9FB-7E21C473096A

Q33257976-6281522F-9F23-4A39-828D-682A7564E714

P304

Q33257976-97FACCF9-355D-4804-ABF4-1E21B10720C8

P31

Q33257976-BF92628A-CEA9-436D-933F-7FE8B11E656B

P356

Q33257976-33EA7576-0B85-474F-89D5-033872F7314B

P407

Q33257976-F31D57B0-6A75-4900-8240-1B13D18EAFDE

P433

Q33257976-CB7AEA82-1D96-4A3A-B28B-98041618A371

P478

Q33257976-0AA5AC65-CC79-4346-B843-0540FD29C947

P50

Q33257976-39698D83-6DC2-497E-ABFC-A1B51C277382

Q33257976-6FD9D9DB-EC2C-4E65-BB25-0EC3013A7BED

Q33257976-A68F1D97-6176-4ADE-8FF8-110AAABDC0B9

Q33257976-BB3EF3E2-1935-4E7D-9222-196F7895881D

Q33257976-CB5835E9-1F48-4BD9-B0E4-406A430D25CE

Q33257976-E0AE1CA1-3B4C-4162-B8A9-905EE9354A84

P577

Q33257976-E4ABDDB7-0540-46DF-83F9-BDDBE9B88248

P5875

Q33257976-1D83BD65-AD4B-43BB-B4BA-55D9F7B06650

P698

Q33257976-BBB363EE-3DE9-4F1C-A0D2-A600343C86B5

P921

Q33257976-E03CC789-C62C-48B5-8868-3FDD12436933

Q33257976-EA0A51AF-DDB9-4A8B-AEF3-F7DF0EEFF0C0

P932

Q33257976-274710F3-B88B-4433-8733-AD3007CE67B7

P356

PNAS.0604144103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Ex vivo pretreatment of bone m ...... nal activity for cell therapy.

@en

P2093

Annisuddin Mohamed

http://www.w3.org/2001/XMLSchema#string

Christopher Heeschen

http://www.w3.org/2001/XMLSchema#string

Hans Martin

http://www.w3.org/2001/XMLSchema#string

Joerg Honold

http://www.w3.org/2001/XMLSchema#string

Ken-ichiro Sasaki

http://www.w3.org/2001/XMLSchema#string

Lothar Rossig

http://www.w3.org/2001/XMLSchema#string

Masamichi Koyanagi

http://www.w3.org/2001/XMLSchema#string

Thomas Ziebart

http://www.w3.org/2001/XMLSchema#string

P2860

Bone marrow cells regenerate infarcted myocardium

Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)

Isolation of putative progenitor endothelial cells for angiogenesis

Nitric oxide synthase modulates angiogenesis in response to tissue ischemia

Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling

Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging.

Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease.

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes

Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve.

P304

14537-14541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0604144103

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Stefanie Dimmeler

Ralf P. Brandes

Alexandra Aicher

P577

2006-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6811432

http://www.w3.org/2001/XMLSchema#string

P698

16983080

http://www.w3.org/2001/XMLSchema#string

P921

P932

1599995

http://www.w3.org/2001/XMLSchema#string